A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to ...
A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to ...
DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G ...
Tags: DTect-All(TM)
Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, ...
Tags: Soligenix, NIAID, ThermoVax, Drs.John Carpenter
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration ...
Tags: Bispecific Antibodies, Sutro's Cell-Free Protein Synthesis Technology
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug ...
Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression) study did not reach its primary endpoint in post-Acute Coronary Syndrome ...
Tags: Cerenis Therapeutics, Phase IIb CHI-SQUARE, post-Acute Coronary Syndrome
Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its ...
Tags: Ocera Therapeutics, Roche, Macrocyclic Template Chemistry
Receptos, a biopharmaceutical company, has announced that Ono Pharmaceuticals has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor ...
Tags: Pharmaceuticals, Receptos
Auxilium Pharmaceuticals, a biopharmaceutical company, has obtained an approval from the US Food and Drug Administration (FDA) for Xiaflex (collagenase clostridium histolyticum) for the treatment of Peyronie's disease. The company claims ...
Tags: Peyronie's Disease Drug, Medicine
InnaVirVax, a biopharmaceutical company, has commenced a Phase II clinical trial evaluating the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. The ...
Agalimmune, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours. The new company has been founded by an investment group comprising Loxbridge ...
Tags: solid tumours, cancer treatment
Signum Dermalogix, a biopharmaceutical company, has announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling ...
Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...
Stemline Therapeutics, a clinical stage biopharmaceutical company, and The Leukemia & Lymphoma Society (LLS), a voluntary health organization, have announced their collaboration to accelerate the development of SL-401 for the treatment of ...